S&P downgrades pharma firm on debt-funded acquisition plans
US pharma firm downgraded on plans to complete its third acquisition of 2011
CLOs
- Middle market portfolios aren't immune to rate stress, according to new research 2 days ago
- Sona prices CLO number two 2 days ago
- Another 2016 vintage CLO gets reset as Octagon stays busy 2 days ago
- Neuberger Berman resets 2016 vintage for second time 2 days ago
- Beach Point brings in tight price for third US CLO 2 days ago